Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Galectin Therapeutics ( (GALT) ) just unveiled an announcement.
Galectin Therapeutics announced the availability of its updated corporate presentation, which highlights promising results from its NAVIGATE trial for belapectin, showing a significant reduction in new varices in patients with MASH cirrhosis. This update underscores the company’s strategic focus on addressing the significant unmet medical need in MASH cirrhosis, potentially enhancing its market position and benefiting stakeholders by providing a novel therapeutic option.
More about Galectin Therapeutics
Galectin Therapeutics is a biopharmaceutical company focused on developing therapeutics for chronic liver diseases and cancer. The company is the only one exclusively targeting MASH cirrhosis and portal hypertension with its novel galectin-3 inhibitor, belapectin, which has demonstrated significant efficacy in clinical trials.
YTD Price Performance: -5.98%
Average Trading Volume: 702,621
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $68.54M
For a thorough assessment of GALT stock, go to TipRanks’ Stock Analysis page.
